Suchergebnisse - "Grosicki, Sebastian"

PubPharm (180)

1

ROP-ET : a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

enthalten in: Annals of hematology | 2024

von Kiladjian, J. | Marin, F. | Al-Ali, H. | +38

2

Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Jagannath, S. | Delimpasi, S. | Grosicki, S. | +4

3

Momelotinib in Myelofibrosis Patients With Thrombocytopenia : Post Hoc Analysis From Three Randomized Phase 3 Trials

enthalten in: HemaSphere | 2023

von Kiladjian, J. | Vannucchi, A. | Gerds, A. | +17

4

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV) : a multicentre, randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Broome, C. | McDonald, V. | Miyakawa, Y. | +83

5

Safety of AFM11 in the treatment of patients with B-cell malignancies: Findings from two phase 1 studies

enthalten in: ResearchSquare.com | 2023

von Topp, M. | Dlugosz-Danecka, M. | Skotnicki, A. | +13

6

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Schiller, G. | Lipe, B. | Bahlis, N. | +22

7

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM) : an updated analysis of an international, double-blind, randomised phase 3 study

enthalten in: The Lancet. Haematology | 2023

von Gerds, A. | Verstovsek, S. | Vannucchi, A. | +25

CommentIn: Lancet Haematol. 2023 Sep;10(9):e697-e699. - PMID 37517412

8

Elranatamab : a new promising BispAb in multiple myeloma treatment

enthalten in: Expert review of anticancer therapy | 2023

von Grosicki, S. | Bednarczyk, M. | Kociszewska, K.

9

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients : An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bringhen, S. | Pour, L. | Benjamin, R. | +11

10

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma : Interim Analysis of a Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Hillmen, P. | Eichhorst, B. | Brown, J. | +25

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]